CNS Pharmaceuticals Engages CRO For Phase 2 Berubicin Clinical Trials

HOUSTON, Aug. 20, 2020 /PRNewswire/ — CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced it has engaged Worldwide Clinical Trials (“Worldwide”) as the contract research organization (“CRO”) for its upcoming Berubicin clinical trials.

The release as fetched from its publisher. cnspharma.com ↗